Amgen beat Q3 2025 earnings estimates, raised guidance and dividends, and boosted stock outlook despite insider selling.

Amgen reported strong Q3 2025 earnings, with $5.64 EPS and $9.56 billion in revenue, surpassing estimates and marking a 12.4% year-over-year increase. The company raised its full-year 2025 EPS guidance to $20.60–$21.40 and boosted its quarterly dividend by 6% to $2.52 per share, yielding 3.1%. Amgen also expanded its pipeline through acquisitions and new trials in oncology and obesity, prompting UBS to upgrade its rating to “Strong Buy.” Despite insider selling, institutional ownership remains high, and analysts maintain a “Moderate Buy” consensus with a $338.55 target. The stock trades near $330.11 with a market cap of $177.76 billion.